Adjuvant chemo-immunotherapy may benefit patients with resected stage IB–IIIA NSCLC, trial suggests
Interim results from the NADIM ADJUVANT Phase III trial, led by the Spanish Lung Cancer Group (GECP), suggest…
A single genetic mutation may have made humans more vulnerable to cancer than chimpanzees
(SACRAMENTO) New research from UC Davis Comprehensive Cancer Center has uncovered an evolutionary change that may explain why…